The ECFS-CTN cannot guarantee that the information provided here is comprehensive. Please go to the ClinicalTrials.gov link for detailed and up-to-date information on study background, eligibility criteria, study design, outcome measures, study status, participating sites, sponsor contact information and timelines.
You can also contact the CTN coordinating centre for additional information: ECFS-CTN@uzleuven.be (link sends e-mail)
| Study Name on ClinicalTrials.gov (link is external) | Efficacy Study of IgY (Antibody Against Pseudomonas) in Cystic Fibrosis Patients (PsAer-IgY) |
|---|---|
| Study Drug | Avian Polyclonal Anti-Pseudomonas Antibodies (IgY) |
| Type of Study Drug | Anti-infective |
| Study Title | Phase III Study to Evaluate Clinical Efficacy and Safety of Avian Polyclonal Anti-Pseudomonas Antibodies (IgY) in Prevention of Recurrence of Pseudomonas Aeruginosa Infection in Cystic Fibrosis Patients |
| Study Phase | 3 |
| Study Sponsor | Mukoviszidose Institut gGmbH |
http://www.clinicaltrials.gov/ct2/show/NCT01455675 Additional information: | |
| Participating ECFS-CTN sites | Belgium: Leuven Germany: Berlin, Frankfurt, Hannover, Cologne Italy: Firenze, Genua, Rome, Verona Spain: Barcelona Sweden: Stockholm |
| Age | 5 years and older |